...
首页> 外文期刊>Journal of Clinical Pharmacy and Therapeutics >Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin
【24h】

Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin

机译:葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症和急性冠脉综合征的患者的抗血小板和侵入性治疗。阿司匹林的安全性

获取原文
获取原文并翻译 | 示例
           

摘要

What is known and objective: Aspirin is an important drug in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). However, its use is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk for haemolytic anaemia). We report the management of 2 patients with class II G6PD deficiency and non-ST-segment elevation ACS (NSTE-ACS).
机译:已知和客观的:阿司匹林是急性冠脉综合征(ACS)和经皮冠状动脉介入治疗(PCI)的重要药物。但是,在葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症(溶血性贫血危险)的患者中,禁止使用它。我们报告2例II类G6PD缺乏和非ST段抬高型ACS(NSTE-ACS)的患者的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号